HYDERABAD, INDIA (April 13, 2015) - Suven Life Sciences Ltd (Suven) today announced that it has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies (MAD) as a part of the Phase I study currently ongoing in USA under US-IND 123179. SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with Alzheimer’s disease and Schizophrenia.
The Phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy volunteers. The tolerability of SUVN-G3031 up to the highest dose administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031 demonstrated excellent pharmacokinetics with a potential for once in a day dosing.
Histaminergic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders. Hence novel, potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for the unmet medical needs in Alzheimer’s disease, Schizophrenia and other CNS disorders.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has eleven (11) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVN-G3031 for Alzheimer’s disease and Schizophrenia.
For more information please visit our Web site at http://www.suven.com
Help employers find you! Check out all the jobs and post your resume.
